VIVUS Files Lawsuit Against Teva For Infringement Of Qsymia Patents

(RTTNews) - VIVUS Inc. (VVUS) announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd., collectively referred to as Teva.

The lawsuit was filed in response to an Abbreviated New Drug Application, or ANDA, filed by Teva. In its application, Teva seeks to market and sell generic versions of the currently approved doses of Qsymia (phentermine and topiramate extended-release) capsules CIV prior to the expiration of U.S. Patents 7,056,890, 7,553,818, 7,659,256, 7,674,776, 8,580,298, 8,580,299, 8,895,057 and 8,895,058, which are listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations, or the Orange Book.

VIVUS filed the lawsuit on the basis that Teva's proposed generic products infringe each of these patents held by VIVUS.